Efficacy & mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D)
21st August 2015
Body: EME
Amount: £725,000
People
| Photo | Name | Bio |
|---|---|---|
 |
Professor Robin Spiller | Robin's main interest is in the pathophysiology of functional GI diseases, particularly focusing on the role of infection and inflammation and alterations in serotonin metabolism in the irritable bowel syndrome. He has twice edited the British Society of… |
